Cargando…
Pomalidomide Shows Significant Therapeutic Activity against CNS Lymphoma with a Major Impact on the Tumor Microenvironment in Murine Models
Primary CNS lymphoma carries a poor prognosis. Novel therapeutic agents are urgently needed. Pomalidomide (POM) is a novel immunomodulatory drug with anti-lymphoma activity. CNS pharmacokinetic analysis was performed in rats to assess the CNS penetration of POM. Preclinical evaluation of POM was per...
Autores principales: | Li, Zhimin, Qiu, Yushi, Personett, David, Huang, Peng, Edenfield, Brandy, Katz, Jason, Babusis, Darius, Tang, Yang, Shirely, Michael A., Moghaddam, Mehran F., Copland, John A., Tun, Han W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3734315/ https://www.ncbi.nlm.nih.gov/pubmed/23940785 http://dx.doi.org/10.1371/journal.pone.0071754 |
Ejemplares similares
-
Pomalidomide-induced changes in the pancreatic tumor microenvironment and potential for therapy
por: Storz, Peter
Publicado: (2019) -
CXCL10/CXCR3 signaling contributes to an inflammatory microenvironment and its blockade enhances progression of murine pancreatic precancerous lesions
por: Pandey, Veethika, et al.
Publicado: (2021) -
Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin’s lymphoma
por: Lurain, Kathryn, et al.
Publicado: (2021) -
Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model
por: Vo, Manh-Cuong, et al.
Publicado: (2018) -
Population Pharmacokinetics of Pomalidomide
por: Li, Yan, et al.
Publicado: (2015)